Investigating Live Circulating Cancer Cells :
One Cell at a Time
CTC Capture
Patented assay ensures live CTC isolation
Comprehensive Multi-omics Panel
Screens 1000+ genes for actionable biomarkers.
Predicting early
Recurrence, Relapse, Treatment resistance
Unprecedented Precision
Accurate multi-omics predictions from single cells
What is OncoIndx Ikon™ ?
Performs capture of live CTCs and downstream molecular profiling of single circulating tumor cells (sCTC) using OncoIndx Ikon™ platform consists of glass beads conjugated with anti EpCAM antibodies to enable precision oncology at a single cell level.
Enables capture and releasing CTCs, without cell fixing in a high throughput manner in multi-well assay plate.
• Validates sCTC mutational profile in real-time using direct matched ctDNA.
• No contamination of leucocytes.
Live sCTC capture and release using OncoIndx Ikon™ kit
OncoIndx Ikon™ Applications
Analytical validation of OncoIndx Ikon™
OncoIndx Ikon™ highlights
Relapse :
Prediction of disease relapse through genomics, transcriptomics and proteomics
Recurrence :
Prediction of recurrence biomarkers, and pathways through genomics, transcriptomics and proteomics
Treatment sensitivity/resistance :
Prediction of drug resistant genes and pathways through ADC profiling
Illustrative Case Study :
Which cancer cell will cause Tumor Metastasis/Progression/Resistance ?
Better Insights => Better Clinical Decisions => Better Outcomes
- Case of a Stage 4, Non small cell lung cancer patient, Male 67
- CGP based on ctDNA did not find any thing
- Found 3 CTCs, analyzed by OncoIndx Ikon™
- Out of 3, 2(CTC2 & CTC3) are molecularly vulnerable & are aggressive cell types : may lead to resistance
- Better insights to propose off-label options such as PARP Inhibitor or Platinum based Chemo-Therapy
OncoIndx Ikon™ CTCs : Triple negative breast cancer
sCTC captured from triple negative Breast cancer patient (Row 1), and Her-2 negative Breast cancer patient (Row 2), using OncoIndx Ikon™
OncoIndx Icon™ CTCs : Breast cancer (Her-2 +ve)
sCTC captured from triple negative Breast cancer patient (Row 1), and Her-2 positive Breast cancer patient (Row 2), using OncoIndx Ikon™
OncoIndx Ikon™ Superiority
OncoIndx Ikon™ in biopharmaceutical companies
• Validating Plasma derived therapies
• Cell biopsy solution for novel cancer therapeutics.
• Clinical validation of molecular property prediction.
• Clinical support for immunological research.
• Target identification, Preclinical studies, Drug screening and MOA analysis, Patient stratification, Response monitoring.
OncoIndx Ikon™ for cancer patients
OncoIndx Ikon™ can help patients with important clinical questions like,
• Tumor evolution and metastasis: Is my cancer at high risk of metastasis?
• Early Cancer recurrence: Is my cancer coming back?
• Unravelling challenging tumor microenvironment: My genomic test was negative.Can OncoRadar™ detect changes that were missed otherwise?
• Disease subtyping and mapping of genotype to phenotype changes: Is my disease aggressive?
• Resistance assessment: Is my treatment working or do I have resistance?
• Tracking of cancer cell heterogeneity: Do I have various mutation population in my tumor mass?
